Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%

View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2020Author
Reid, MichelleBalcı, Serdar
Bağcı, Pelin
Saka, Burcu
Pehlivanoğlu, Burçin
Erbarut Seven, İpek
Baştürk, Olca
Adsay, N. Volkan
Metadata
Show full item recordCitation
Reid, M., Balcı, S., Bağcı, P., Saka, B., Pehlivanoğlu, B., Erbarut Seven, İ. ... Adsay, N. V. (2020). Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) içinde (1673-1673. ss.). Los Angeles, CA, February 29-March 05, 2020.Abstract
Background: Grading of linear parameters into meaningful (clinically relevant) clusters is a well-known challenge. Recently several groupshave proposed to change the Ki67 index cut-off for grade 1 (G1) category for PanNETs from < 3% to < 5%. This proposal presupposes thatthe cases with Ki67 index of 3-5% are NOT clinically different than the 0-3% group and thus can be lumped together with the current G1 (0-3% cases), instead of their current home in the G2 category (> 3%).
WoS Q Kategorisi
Q1Source
109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)Volume
33Issue
Supplement: 2Collections
- Bildiri Koleksiyonu [485]
- WoS İndeksli Yayınlar Koleksiyonu [5979]